Unlike existing state-of-the-art technologies and preclinical diagnostic tests, KScan® uses proprietary computational algorithms to interrogate the phosphoproteome and identify clinically precise biomarkers for more accurate drug monitoring and efficacy predictions, which could lead to signiﬁcant improvements in patient stratiﬁcation.
Discover how our labs can support your drug discovery and development at the preclinical stage and Phase I. Save time and reduce costs with our tailored services and insights!
Identify novel drug targets
Investigate Mode of Action / Drug Resistance Mechanisms
Elucidate Off-Target Effects
Stratify patients for Clinical Trials
Rescue Failed Drugs
Kinomica provides bespoke R&D and diagnostic services to meet specific customer needs and inform diagnostic decision-making.
Talk to our Experts
To find out more about the technology behind Kinomica’s advanced bioinformatics and phosphoproteomics analytical methods, talk to our experts.
If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.
“Our technology can look at over 10,000 proteins in one simple experiment and tell researchers exactly which proteins are activated and deactivated. This is hugely important and relevant for personalised medicine“
Jane Theaker, Kinomica CEO